Biogen Inc. (BIIB)

273.28
NASDAQ
Prev Close 270.04
Day Low/High 267.50 / 274.26
52 Wk Low/High 219.70 / 374.99
Exchange NASDAQ
Shares Outstanding 158.31B
Market Cap 42.75B
P/E Ratio 7.93
Div & Yield N.A. (N.A)
Cramer: Confusion Reigns in This Market

Cramer: Confusion Reigns in This Market

Many want to undo what's been done, but not enough to send the market down.

Midday Report: Biogen Weighs on Health Care Stocks; U.S. Markets Fall

Midday Report: Biogen Weighs on Health Care Stocks; U.S. Markets Fall

Stocks give back earlier gains as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.

Biogen downgraded at Leerink

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Biogen upgraded at Citi

There Is So Little Attention Paid to the Fed Meeting

There Is So Little Attention Paid to the Fed Meeting

The Fed is simply not a market catalyst this time.

5 Reasons Why Celgene Should Buy Competitor Biogen

5 Reasons Why Celgene Should Buy Competitor Biogen

There are several reasons why Celgene should buy Biogen.

5 Reasons Celgene Should Buy Biogen

5 Reasons Celgene Should Buy Biogen

A merger would be smart, profitable ... and attention-grabbing.

Biogen Resolves Multiple Sclerosis Drug Dispute

Biogen Resolves Multiple Sclerosis Drug Dispute

Shares of Biogen were lower Tuesday after the company resolved a dispute with Forward Pharma over its multiple sclerosis drug.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Biogen Could Suffer Near Term as the Chart Picture Erodes

Biogen Could Suffer Near Term as the Chart Picture Erodes

With weak chart patterns and a quantitative downgrade, longs should protect their positions.

Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval

Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval

The U.S. Food and Drug Administration approved the biotech company's treatment for spinal muscular atrophy late Friday.

My Top Pick for 2017: Short QQQ

My Top Pick for 2017: Short QQQ

Six reasons why the Nasdaq 100 ETF seems ready to pull back.

My Top Pick for 2017: Short QQQ

My trade of the year for 2017 is to short the PowerShares QQQ Trust ETF , which tracks the Nasdaq 100 index. Here's my investment thesis for this play: The Nasdaq 100 Already Has Rallied QQQ already has risen from about $96 a share at the market's F...

Sellers Are Dominating the Price Action in Biogen

Sellers Are Dominating the Price Action in Biogen

Shoppers may want to wait until after the holidays for a bargain on BIIB.

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

The bullish side dominates, with consumer cyclicals and energy names most prevalent.

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Midday Report: Stocks Higher As Wall Street Shrugs Off Trump's Presidential Election

Midday Report: Stocks Higher As Wall Street Shrugs Off Trump's Presidential Election

U.S. stocks rallied slightly in midday trading as energy, financials, and healthcare sectors saw green on Wednesday following the surprise election of Republican Donald Trump.

Biogen Sees Positive Drug Study Results

Biogen Sees Positive Drug Study Results

Shares of Biogen were higher on Monday after the biotech company and Ionis Pharmaceuticals said their Phase 3 trial of its spinal muscular atrophy drug met its primary endpoint.

Biogen upgraded at Piper

Midday Report: Apple Rallies for Day Two; U.S. Stocks Climb After Extreme Three Days

Midday Report: Apple Rallies for Day Two; U.S. Stocks Climb After Extreme Three Days

U.S. stocks bounced around in the green in far more stable trading following three days of extreme swings.

Biotech May Be About to Rescusitate

Biotech May Be About to Rescusitate

Check out this biotech ETF, and Biogen, for plays on any recovery.

Biogen downgraded at Jefferies